Joseph Fridman
Director of Communications and Corporate Affairs, Ginkgo
Replay available
Ginkgo Bioworks Holdings Inc (DNA) Q4 2024 Earnings Call
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Q4 2024 earnings conference call, held 2025-02-25. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Jason Kelly
Co-Founder and CEO, Ginkgo
Mark Dimitrick
CFO, Ginkgo
Jason Overtages
Analyst, Morgan Stanley
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Ginkgo Bioworks Holdings, Inc..
Replay transcript excerpt
WEBVTT 00:00:01.178 -- 00:00:05.305 Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here 00:00:05.305 -- 00:00:09.211 at Ginkgo, where it's my fifth year. During that time, I've had the pleasure and the 00:00:09.211 -- 00:00:13.497 privilege of working with our investor relations team, usually behind the scenes of these 00:00:13.497 -- 00:00:17.344 earning calls. And so it's exciting to be supporting you today in this more front-facing 00:00:17.344 -- 00:00:22.652 role. I'm joined by Jason Kelly, our co-founder and CEO, and Mark Dimitrick, 00:00:22.652 -- 00:00:27.520 our CFO. Thanks as always for joining us. We're really looking forward to updating you 00:00:27.520 -- 00:00:30.018 on our progress today. 00:00:30.018 -- 00:00:34.423 As a reminder, during the presentation today, we will be making forward-looking statements. 00:00:34.423 -- 00:00:38.488 These involve risks and uncertainties. So please refer to our filings with the SEC to 00:00:38.488 -- 00:00:43.871 learn more about these risks and uncertainties, including in our most recent 10-K. 00:00:44.074 -- 00:00:47.498 Today, in addition to updating you on the quarter and the full year results, we're going 00:00:47.498 -- 00:00:52.423 to provide updates on our path towards adjusted EBITDA breakeven, as well as customer 00:00:52.423 -- 00:00:58.081 progress in our cell engineering business across both our services and tools offerings. 00:00:58.081 -- 00:01:01.305 and the latest offerings in our biosecurity business. 00:01:01.305 -- 00:01:06.051 As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors, 00:01:06.051 -- 00:01:10.796 and the public. You can submit questions for that to us in advance via X. 00:01:10.796 -- 00:01:14.561 Please tag your ...